Iovance Biotherapeutics

Today at the SITC Spring Scientific meeting, EVP of Translational Medicine & Research, Brian Gastman, will present preclinical data for IOV-5001, a next generation, genetically engineered TIL therapy: iovance.com/scientific-pub…

#MucosalMelanoma represents ~1% of melanoma diagnoses and is often found in “hidden” areas, leading to delayed diagnosis. Raising awareness can help people recognize symptoms sooner and connect with trusted resources. At Iovance, we are committed to supporting this community.

Our EVP of Translational Medicine & Research, Brian Gastman, and Head of Investor Relations and Corporate Communications, Sara Pellegrino, will participate in a fireside chat at the Barclays 28th Annual Healthcare Conference today. Register here: ir.iovance.com/events/event-d…

Iovance CFO Corleen Roche and COO Igor Bilinsky will participate in a presentation and fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston today. Register here for the live webcast or replay: ir.iovance.com/events/event-d…

Earlier this week, we shared exciting clinical results in two aggressive forms of advanced soft tissue sarcoma, illustrating the promise of our TIL cell therapy platform to offer meaningful clinical benefit in multiple solid tumor cancers: ir.iovance.com/news-releases/…

Today, Iovance reported fourth quarter and full year 2025 financial results, business achievements and corporate updates. We will host an audio webcast at 8:30 am ET today, join live or listen to the replay: ir.iovance.com/news-events/ev…

Are you attending #IO360 Summit? Hear our COO Igor Bilinsky, PhD discuss the Iovance experience and how we're leading the future of TIL therapy for patients with solid tumors. #TIL #ImmunoOncology

A real world analysis of our cell therapy in patients with previously treated advanced melanoma is featured at #Tandem26: ir.iovance.com/news-releases/…

On #WorldCancerDay, we recognize the courage and power of the voices behind every statistic. This Melanoma Research Foundation video underscores why we are committed to advancing cancer research: youtube.com/watch?app=desk…

A real world study of our cell therapy in patients with advanced melanoma will be presented at #Tandem26 in Salt Lake City next week! View presentation details here: tandem.virtual-meeting.org/programme/pres…

As the global leader in TIL therapy, we are advancing solutions for cancer patients who need them most. We look forward to seeing our investors and analysts in San Francisco! #CellTherapy #TILTherapy #Immunotherapy #Melanoma #NSCLC ir.iovance.com/news-events/ev…

Today we reported third quarter and year to date 2025 financial results, business achievements and pipeline milestones. We hosted an audio webcast at 8:30 am ET today, listen to our audio webcast here: ir.iovance.com/events/event-d…

We announced positive interim data for our one-time cell therapy in advanced NSCLC: ir.iovance.com/news-releases/…

We’re just ONE day away from the 24th Annual NYC Gala! We’re thrilled to welcome @CaptJChambers, Superyacht Captain, TV personality, melanoma patient and advocate as this year’s emcee. Jason brings powerful energy, authenticity and purpose to this special night as we come together to celebrate hope, connection and impact in the fight against melanoma. Join us tomorrow, October 30, at Cipriani Broadway for an unforgettable evening but hurry, tickets are almost gone! Can’t make it in person? You can still make a difference by donating to support life-saving melanoma research and patient programs. Click the link to secure your ticket or make your gift today: us.givergy.com/MRFNYGala25

If you’re in Berlin for #ESMO25, visit us at Booth 3025! Analyses from our C-144-01 clinical trial for our therapy in advanced melanoma will be included in Monday’s poster session, view the poster here: iovance.com/scientific-pub…

We're excited to have Laurel Todd, our Head of Policy and Market Access Operations, representing Iovance at #CGMesa25 today. Tune in for her perspectives regarding the impact of MFN and tariffs to the CGT sector. ​meetingonthemesa.com

Our team is excited for @alliancerm's #CGMesa25! Check out our CCO Dan Kirby as he joins fellow industry leaders and innovators on the stage today. meetingonthemesa.com

Iovance is sponsoring @alliancerm’s #CGMesa25, North America's leading gathering of experts and leadership in the cell & gene therapy sector. Check out our Iovance panelists as they join forces with industry pioneers to shape the future of healthcare. MeetingontheMesa.com

Four years ago today, we officially marked the opening of the Iovance Cell Therapy Center (iCTC) in Philadelphia as the first U.S. facility dedicated to manufacturing TIL cell therapies! Learn more about iCTC and cell therapy manufacturing: iovance.com/iovance-cell-t…

On #WorldCancerResearchDay, we honor the patients and researchers driving progress in #cancerresearch. At Iovance, we’re advancing cell therapy research with the goal to bring new hope to people with solid tumor cancers. Learn about our clinical trials: tilcelltherapy.com